Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, and Immunogenicity of the Dengue 1, 2, 3, 4 (Attenuated) Vaccine From Instituto Butantan

NCT02406729 is registered in ClinicalTrials.gov with Butantan Institute as lead sponsor.

NCT NCT02406729
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02406729 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, and Immunogenicity of the Dengue 1, 2, 3, 4 (Attenuated) Vaccine From Instituto Butantan
Lead sponsor
Butantan Institute
Phase
Phase 3
Overall status
Unknown status
Start date
February 22, 2016
Completion date
November 30, 2024
Enrollment
16,935 (estimated)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

dengue